Pharvaris Stock Forecast, Price & News

Pharvaris (NASDAQ:PHVS) Frequently Asked Questions

Is Pharvaris a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pharvaris in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Pharvaris stock.
View analyst ratings for Pharvaris or view top-rated stocks.

Are investors shorting Pharvaris?

Pharvaris saw a decline in short interest in November. As of November 15th, there was short interest totaling 68,400 shares, a decline of 74.8% from the October 31st total of 271,000 shares. Based on an average daily trading volume, of 27,200 shares, the days-to-cover ratio is presently 2.5 days. Currently, 0.3% of the shares of the stock are sold short.
View Pharvaris' Short Interest.

When is Pharvaris' next earnings date?

Pharvaris is scheduled to release its next quarterly earnings announcement on Thursday, May 5th 2022.
View our earnings forecast for Pharvaris.

How were Pharvaris' earnings last quarter?

Pharvaris (NASDAQ:PHVS) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.39) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.49) by $0.10.
View Pharvaris' earnings history.

What price target have analysts set for PHVS?

4 brokerages have issued twelve-month price targets for Pharvaris' shares. Their forecasts range from $41.00 to $51.00. On average, they expect Pharvaris' stock price to reach $47.50 in the next year. This suggests a possible upside of 222.5% from the stock's current price.
View analysts' price targets for Pharvaris or view top-rated stocks among Wall Street analysts.

Who are Pharvaris' key executives?

Pharvaris' management team includes the following people:

• Mr. Berndt A. E. Modig M.B.A., MBA, CPA, Co-Founder, CEO & Exec. Director (Age 62)
• Ms. Anna Nijdam M.Sc., R.A., Head of Fin. & Principal Accounting Officer (Age 39)
• Dr. Jochen Knolle, Chief Scientific Officer & COO (Age 71)
• Dr. Peng Lu M.D., Ph.D., Chief Medical Officer (Age 43)
• Dr. Anne Lesage Ph.D., Chief Early Devel. Officer (Age 60)
• Dr. Morgan Conn Ph.D., Chief Bus. Officer (Age 52)

Who are some of Pharvaris' key competitors?

Some companies that are related to Pharvaris include Dynavax Technologies (DVAX), Ironwood Pharmaceuticals (IRWD), Global Blood Therapeutics (GBT), Atai Life Sciences (ATAI), Travere Therapeutics (TVTX), Morphic (MORF), Enanta Pharmaceuticals (ENTA), Erasca (ERAS), Kadmon (KDMN), Bicycle Therapeutics (BCYC), IVERIC bio (ISEE), Supernus Pharmaceuticals (SUPN), Verve Therapeutics (VERV), Rocket Pharmaceuticals (RCKT) and IGM Biosciences (IGMS).
View all of PHVS's competitors.

When did Pharvaris IPO?

(PHVS) raised $126 million in an IPO on Friday, February 5th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers.

What is Pharvaris' stock symbol?

Pharvaris trades on the NASDAQ under the ticker symbol "PHVS."

Who are Pharvaris' major shareholders?

Pharvaris' stock is owned by many different retail and institutional investors. Top institutional investors include Deerfield Management Company L.P. Series C (5.05%), VR Adviser LLC (1.74%), Millennium Management LLC (0.50%), Goldman Sachs Group Inc. (0.09%), Morgan Stanley (0.06%) and Compagnie Lombard Odier SCmA (0.05%).

Which institutional investors are selling Pharvaris stock?

PHVS stock was sold by a variety of institutional investors in the last quarter, including VR Adviser LLC, Millennium Management LLC, and Morgan Stanley.

Which institutional investors are buying Pharvaris stock?

PHVS stock was acquired by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, Goldman Sachs Group Inc., and Compagnie Lombard Odier SCmA.

How do I buy shares of Pharvaris?

Shares of PHVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pharvaris' stock price today?

One share of PHVS stock can currently be purchased for approximately $14.73.

How much money does Pharvaris make?

Pharvaris has a market capitalization of $469.00 million.

How many employees does Pharvaris have?

Pharvaris employs 14 workers across the globe.

What is Pharvaris' official website?

The official website for Pharvaris is www.pharvaris.com.

How can I contact Pharvaris?

The company can be reached via phone at 31-71-203-6410.